Cutaneous reactions to recombinant cytokine therapy.
Cytokines are critical to several fundamental homeostatic mechanisms such as fever, acute phase reactions, wound healing, hematopoiesis, inflammation, cellular and humoral immune responses, and tumor regression. As a result of advances in recombinant DNA technology, recombinant cytokines are available as therapeutic agents. They have been used for metastatic cancers and immunodeficiencies, as a therapy for naturally occurring or drug-induced anemias or leukopenias, and they have also been applied to some cutaneous disorders. Cytokine therapy can result in toxic reactions that affect many organ systems, especially the skin. These reactions are common and diverse, ranging from minor injection site reactions, pruritus, and flushing to life-threatening autoimmune disorders, severe erythroderma, or bullous skin reactions. This review focuses on the major cytokines that are in current clinical use or under investigation and describes the cutaneous complications of these agents.
Asnis
L A
LA
Department of Medicine, University of Rochester School of Medicine and Dentistry, NY, USA.
Gaspari
A A
AA
D001327:Autoimmune Diseases / Q000209:etiology; D016207:Cytokines / Q000009:adverse effects* / Q000145:classification / Q000502:physiology / Q000627:therapeutic use; D003873:Dermatitis, Exfoliative / Q000209:etiology; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D007372:Interferons / Q000009:adverse effects; D007378:Interleukins / Q000009:adverse effects; D009369:Neoplasms / Q000628:therapy; D011994:Recombinant Proteins; D012871:Skin Diseases / Q000209:etiology*; D012872:Skin Diseases, Vesiculobullous / Q000209:etiology
D016207:Cytokines; D007378:Interleukins; D011994:Recombinant Proteins; D007372:Interferons